AstraZeneca PLC
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Fasenra (benralizumab) — Established RoW YoY CER by Year
Fasenra (benralizumab) — Established RoW YoY CER (%) (%)
AstraZeneca Fasenra (benralizumab) — Established RoW YoY CER: 30.0% in FY2025, up 24.0 pts from a year earlier.
Latest, FY2025
30.0%
Period ended Dec 31, 2025
Change on a year earlier
+24.0 pts
6.0% in FY2024
History
6 years
Since FY2020
Sources
6
Documents cited below
Where the FY2025 figure comes from
“|| Fasenra | 1,981 | 17 | 16 | 1,195 | 14 | 117 | 27 | 29 | 482 | 19 | 15 | 187 | 29 | 30”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Fasenra (benralizumab) — Established RoW YoY CER (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 30.0% | +24.0 pts | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 6.0% | 0.0 pts | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 6.0% | +7.0 pts | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | -1.0% | -23.0 pts | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | 22.0% | -10.0 pts | Form 6-K FY2021Q4 Earnings Release ↗ |
| FY2020 | Dec 31, 2020 | 32.0% | – | Form 6-K FY2020Q4 Earnings Release ↗ |
Cite this data
StockData. (2026). AstraZeneca Fasenra (benralizumab) — Established RoW YoY CER (%), annual FY2020–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-fasenra-erow-cer-yoy
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.